Delving into the Latest Updates on 3HP-2827 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2000 (3H Pharmaceuticals), N-(4-(4-Amino-7-cyano-1-methyl-3-(4-((4-methylpyrimidin-2-yl)oxy)phenyl)-1H-pyrrolo[3,2-c]pyridin-2-yl)-3-methylphenyl)methacrylamide

+ [2]

Target

FGFR2

Mechanism

FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists)

Therapeutic Areas

Neoplasms

Active Indication

FGFR2 Mutation Solid TumorsSolid tumorFGFR2 Mutant Neoplasms

Inactive Indication-

Originator Organization

3H (Suzhou) Pharmaceuticals Co., Ltd

Active Organization

3H (Shanghai) Pharmaceuticals Co., Ltd3H (Suzhou) Pharmaceuticals Co., Ltd

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

RegulationFast Track (US), Orphan Drug (US)

Login to view timeline

The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations. Patients will be enrolled in two stages: dose escalation stage (Stage I) and expansion stage (Stage II).

Start Date01 Jun 2024

Sponsor / Collaborator

3H (Suzhou) Pharmaceuticals Co., Ltd

100 Clinical Results associated with 3HP-2827

Login to view more data

100 Translational Medicine associated with 3HP-2827

Login to view more data

100 Patents (Medical) associated with 3HP-2827

Login to view more data

100 Deals associated with 3HP-2827

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
FGFR2 Mutation Solid Tumors	Phase 2	CN	3H (Suzhou) Pharmaceuticals Co., Ltd	17 Jun 2024
Solid tumor	Phase 2	CN	3H (Suzhou) Pharmaceuticals Co., Ltd	17 Jun 2024
FGFR2 Mutant Neoplasms	Phase 2	CN	3H (Suzhou) Pharmaceuticals Co., Ltd	06 Jun 2024